Cargando…

Inhibition of NF-kB/IL-6/JAK2/STAT3 Pathway and Epithelial-Mesenchymal Transition in Breast Cancer Cells by Azilsartan

Metastatic breast cancer is an incurable form of breast cancer that exhibits high levels of epithelial-mesenchymal transition (EMT) markers. Angiotensin II has been linked to various signaling pathways involved in tumor cell growth and metastasis. The aim of this study is to investigate, for the fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Alaaeldin, Rania, Ali, Fares E. M., Bekhit, Amany Abdlrehim, Zhao, Qing-Li, Fathy, Moustafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693603/
https://www.ncbi.nlm.nih.gov/pubmed/36431925
http://dx.doi.org/10.3390/molecules27227825
_version_ 1784837585923735552
author Alaaeldin, Rania
Ali, Fares E. M.
Bekhit, Amany Abdlrehim
Zhao, Qing-Li
Fathy, Moustafa
author_facet Alaaeldin, Rania
Ali, Fares E. M.
Bekhit, Amany Abdlrehim
Zhao, Qing-Li
Fathy, Moustafa
author_sort Alaaeldin, Rania
collection PubMed
description Metastatic breast cancer is an incurable form of breast cancer that exhibits high levels of epithelial-mesenchymal transition (EMT) markers. Angiotensin II has been linked to various signaling pathways involved in tumor cell growth and metastasis. The aim of this study is to investigate, for the first time, the anti-proliferative activity of azilsartan, an angiotensin II receptor blocker, against breast cancer cell lines MCF-7 and MDA-MB-231 at the molecular level. Cell viability, cell cycle, apoptosis, colony formation, and cell migration assays were performed. RT-PCR and western blotting analysis were used to explain the molecular mechanism. Azilsartan significantly decreased the cancer cells survival, induced apoptosis and cell cycle arrest, and inhibited colony formation and cell migration abilities. Furthermore, azilsartan reduced the mRNA levels of NF-kB, TWIST, SNAIL, SLUG and bcl2, and increased the mRNA level of bax. Additionally, azilsartan inhibited the expression of IL-6, JAK2, STAT3, MMP9 and bcl2 proteins, and increased the expression of bax, c-PARP and cleaved caspase 3 protein. Interestingly, it reduced the in vivo metastatic capacity of MDA-MBA-231 breast cancer cells. In conclusion, the present study revealed, for the first time, the anti-proliferative, apoptotic, anti-migration and EMT inhibition activities of azilsartan against breast cancer cells through modulating NF-kB/IL-6/JAK2/STAT3/MMP9, TWIST/SNAIL/SLUG and apoptosis signaling pathways.
format Online
Article
Text
id pubmed-9693603
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96936032022-11-26 Inhibition of NF-kB/IL-6/JAK2/STAT3 Pathway and Epithelial-Mesenchymal Transition in Breast Cancer Cells by Azilsartan Alaaeldin, Rania Ali, Fares E. M. Bekhit, Amany Abdlrehim Zhao, Qing-Li Fathy, Moustafa Molecules Article Metastatic breast cancer is an incurable form of breast cancer that exhibits high levels of epithelial-mesenchymal transition (EMT) markers. Angiotensin II has been linked to various signaling pathways involved in tumor cell growth and metastasis. The aim of this study is to investigate, for the first time, the anti-proliferative activity of azilsartan, an angiotensin II receptor blocker, against breast cancer cell lines MCF-7 and MDA-MB-231 at the molecular level. Cell viability, cell cycle, apoptosis, colony formation, and cell migration assays were performed. RT-PCR and western blotting analysis were used to explain the molecular mechanism. Azilsartan significantly decreased the cancer cells survival, induced apoptosis and cell cycle arrest, and inhibited colony formation and cell migration abilities. Furthermore, azilsartan reduced the mRNA levels of NF-kB, TWIST, SNAIL, SLUG and bcl2, and increased the mRNA level of bax. Additionally, azilsartan inhibited the expression of IL-6, JAK2, STAT3, MMP9 and bcl2 proteins, and increased the expression of bax, c-PARP and cleaved caspase 3 protein. Interestingly, it reduced the in vivo metastatic capacity of MDA-MBA-231 breast cancer cells. In conclusion, the present study revealed, for the first time, the anti-proliferative, apoptotic, anti-migration and EMT inhibition activities of azilsartan against breast cancer cells through modulating NF-kB/IL-6/JAK2/STAT3/MMP9, TWIST/SNAIL/SLUG and apoptosis signaling pathways. MDPI 2022-11-13 /pmc/articles/PMC9693603/ /pubmed/36431925 http://dx.doi.org/10.3390/molecules27227825 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Alaaeldin, Rania
Ali, Fares E. M.
Bekhit, Amany Abdlrehim
Zhao, Qing-Li
Fathy, Moustafa
Inhibition of NF-kB/IL-6/JAK2/STAT3 Pathway and Epithelial-Mesenchymal Transition in Breast Cancer Cells by Azilsartan
title Inhibition of NF-kB/IL-6/JAK2/STAT3 Pathway and Epithelial-Mesenchymal Transition in Breast Cancer Cells by Azilsartan
title_full Inhibition of NF-kB/IL-6/JAK2/STAT3 Pathway and Epithelial-Mesenchymal Transition in Breast Cancer Cells by Azilsartan
title_fullStr Inhibition of NF-kB/IL-6/JAK2/STAT3 Pathway and Epithelial-Mesenchymal Transition in Breast Cancer Cells by Azilsartan
title_full_unstemmed Inhibition of NF-kB/IL-6/JAK2/STAT3 Pathway and Epithelial-Mesenchymal Transition in Breast Cancer Cells by Azilsartan
title_short Inhibition of NF-kB/IL-6/JAK2/STAT3 Pathway and Epithelial-Mesenchymal Transition in Breast Cancer Cells by Azilsartan
title_sort inhibition of nf-kb/il-6/jak2/stat3 pathway and epithelial-mesenchymal transition in breast cancer cells by azilsartan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693603/
https://www.ncbi.nlm.nih.gov/pubmed/36431925
http://dx.doi.org/10.3390/molecules27227825
work_keys_str_mv AT alaaeldinrania inhibitionofnfkbil6jak2stat3pathwayandepithelialmesenchymaltransitioninbreastcancercellsbyazilsartan
AT alifaresem inhibitionofnfkbil6jak2stat3pathwayandepithelialmesenchymaltransitioninbreastcancercellsbyazilsartan
AT bekhitamanyabdlrehim inhibitionofnfkbil6jak2stat3pathwayandepithelialmesenchymaltransitioninbreastcancercellsbyazilsartan
AT zhaoqingli inhibitionofnfkbil6jak2stat3pathwayandepithelialmesenchymaltransitioninbreastcancercellsbyazilsartan
AT fathymoustafa inhibitionofnfkbil6jak2stat3pathwayandepithelialmesenchymaltransitioninbreastcancercellsbyazilsartan